Characteristics of Populations Included in Randomized Controlled Trials of Hemodiafiltration and Registry Real-Life Populations
Clinical Journal of the American Society of Nephrology · 2026-01 · 21 (1) · 95-107
DOI: 10.2215/cjn.0000000855 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Journal of the American Society of Nephrology, online erschienen am 12.09.2025. Verfasst von Krister Cromm und 14 weiteren Autor:innen. Beteiligte Einrichtung: Fresenius Medical Care Deutschland GmbH, Global Medical Office, Bad Homburg, Germany. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Horizon 2020.
Abstract (Originalsprache)
Key Points Coverage of patient characteristics in existing trials of hemodiafiltration versus hemodialysis seems to be broad but incomplete. Randomized trials of hemodiafiltration versus hemodialysis have been primarily limited to Europe. Inconsistencies between trials and registries support further studies using real-world data to explore applicability of existing evidence.
Background
Selection criteria in randomized trials (randomized controlled trials [RCTs]) can lead to differences in key characteristics between trial participants and real-life populations. We evaluated reporting of population characteristics in existing RCTs of hemodiafiltration (HDF) and in real-life populations included in kidney registries to descriptively identify key differences.
Methods
We used systematic review methodology to identify existing RCTs of HDF versus hemodialysis (1966 to May 2024). We also searched the Fresenius Quantitative Market Analysis team registry database (2024 update) for existing registries from Europe, the Asia-Pacific region, and America including populations on HDF. Patient characteristics from RCTs and registries were extracted, summarized, and compared descriptively.
Results
Eleven RCTs ( N =5108) and eight registries ( N =1,147,167) were identified. There were no RCTs in the United States and only two small RCTs from Australia ( N =124) and Brazil ( N =195). Most trials were from Europe. Key characteristics consistently reported in both RCTs and registries were only age, sex, diabetes, cardiovascular disease, vascular access type, and dialysis vintage. There was moderate to high heterogeneity for these patient characteristics in RCTs, indicating enrollment of a broad array of people. The proportion of people with diabetes was 26% in RCTs and 43% in registries. The prevalence of arteriovenous fistulas/graft was 90% in RCTs and 70% in registries.
Conclusions
There was a broad but incomplete array of patient characteristics in existing RCTs and real-world registries of HDF versus hemodialysis. Data were primarily limited to Europe and only a core set of demographic and clinical variables. Apart for age, sex, diabetes, cardiovascular disease, vascular access type, and dialysis vintage, other patient and treatment relevant characteristics were erratically or not at all reported in RCTs as well as in real-world registries. With potential differences in patient populations, we support the need for studies examining HDF in real-world settings, e.g ., with target emulation trials.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Fresenius Medical Care Deutschland GmbH, Global Medical Office, Bad Homburg, Germany.
- Department of Psychosomatic Medicine, Charité - Universitätsmedizin Berlin, Berlin, Germany.
- Fresenius Medical Care Asia Pacific Ltd., Global Medical Office, Hong Kong.
- Department of Precision and Regenerative Medicine and Ionian Area (Dimepre-J), University of Bari, Bari, Italy.
- School of Public Health, University of Sydney, Sydney, New South Wales, Australia.
- Division of Nephrology, Department of Clinical Sciences, Lund University, Lund, Sweden.
ORCID-Profile: Krister Cromm, Ngoc Pham, Jörgen Hegbrant, Mark Woodward, Andrew Davenport, Bernard Canaud, Claudia Barth, Michiel L Bots
Förderung
- Horizon 2020
Zitieren
APA
Cromm, K., Pham, N., Yuen, T., Jaha, H., Saglimbene, V., Hegbrant, J., Woodward, M., Davenport, A., Canaud, B., Barth, C., Rose, M., Blankestijn, P. J., Bots, M. L., Strippoli, G. F. M., & CONVINCE Scientific Committee and Investigators (2026). Characteristics of Populations Included in Randomized Controlled Trials of Hemodiafiltration and Registry Real-Life Populations. Clinical Journal of the American Society of Nephrology, 21(1), 95-107. https://doi.org/10.2215/cjn.0000000855
Vancouver
Cromm K, Pham N, Yuen T, Jaha H, Saglimbene V, Hegbrant J, et al. Characteristics of Populations Included in Randomized Controlled Trials of Hemodiafiltration and Registry Real-Life Populations. Clinical Journal of the American Society of Nephrology. 2026;21(1):95-107. doi:10.2215/cjn.0000000855
BibTeX
@article{Cromm2026,
author = {Cromm, Krister and Pham, Ngoc and Yuen, Tom and Jaha, Hanna and Saglimbene, Valeria and Hegbrant, Jörgen and Woodward, Mark and Davenport, Andrew and Canaud, Bernard and Barth, Claudia and Rose, Matthias and Blankestijn, Peter J and Bots, Michiel L and Strippoli, Giovanni F M and CONVINCE Scientific Committee and Investigators, CONVINCE Scientific Committee and Investigators},
title = {Characteristics of Populations Included in Randomized Controlled Trials of Hemodiafiltration and Registry Real-Life Populations},
journal = {Clinical Journal of the American Society of Nephrology},
year = {2026},
volume = {21},
number = {1},
pages = {95--107},
doi = {10.2215/cjn.0000000855}
}
EUVIMED